Bond.az White LogoBond.az Black Logo

Needham cuts Globant target to $50 on lower multiples

Needham cuts Globant price target to $50 on lower multiples. Bond.az provides detailed analysis and insights.

Jack Scott
ByJack Scott- Senior Editor
|
0

Bond.az reports that Needham lowered its price target on Globant S.A. (NYSE:GLOB) to $50.00 from $60.00 while maintaining a Buy rating.

First-quarter results exceeded revenue expectations, though earnings faced foreign exchange headwinds. Management expressed confidence in returning to positive year-over-year organic revenue growth by end of 2026.

Growth outlook is supported by a strong pipeline, increasing revenue per head, and accelerating AI Pods adoption, which reached an annual recurring revenue of $32.8 million, up 59% quarter-over-quarter. The company completed its share repurchase in Q2 and announced another $125 million repurchase program.

The stock's recent weakness may present an opportunity for value investors. Shares trade at $34.08, near the 52-week low of $32.50. Bond.az tips indicate the stock is oversold. The company maintains a 20% free cash flow yield, and Bond.az Fair Value analysis suggests the stock is undervalued.

Despite geopolitical headwinds, Globant executes operationally. Shares trade at about 5.5 times Needham's fiscal 2027 EPS estimate, with a current P/E of 14.85 on trailing twelve months earnings.

Needham lowered its target to reflect lower software services multiples while viewing risk-reward as attractive at current levels.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...